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Abstract: Allergic diseases are on the rise globally, in parallel with a 
decline in parasitic infection. The inverse association between parasitic 
infections and allergy at an ecological level suggests a causal 
association. Studies in humans have generated a large knowledge base on 
the complexity of the inter-relationship between parasitic infection and 
allergy. There is evidence for causal links, but the data from animal 
models are the most compelling: despite the strong Type 2 immune 
responses they induce, helminth infections can suppress allergy through 
regulatory pathways. Conversely, many helminths may cause allergic-type 
inflammation including symptoms of "classical" allergic disease. From an 
evolutionary perspective, individuals with an effective immune response 
against helminths may be more susceptible to allergy. This narrative 
review aims to inform readers on the most relevant up to date evidences 
on the relationship between parasites and allergy. Experiments in animal 
models have demonstrated the potential benefits of helminth infection or 
administration of helminth-derived molecules on chronic inflammatory 
diseases, but clinical trials in humans have not so far demonstrated 
unequivocal clinical benefits. Nevertheless, there is sufficiently strong 
evidence to support the continued investigation of the potential benefits 
of helminth-derived therapies for the prevention or treatment of allergic 
and other inflammatory diseases. 
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Abstract 35 
Allergic diseases are on the rise globally, in parallel with a decline in parasitic infection. The 36 
inverse association between parasitic infections and allergy at an ecological level suggests a 37 
causal association. Studies in humans have generated a large knowledge base on the 38 
complexity of the inter-relationship between parasitic infection and allergy. There is evidence 39 
for causal links, but the data from animal models are the most compelling: despite the strong 40 
Type 2 immune responses they induce, helminth infections can suppress allergy through 41 
regulatory pathways. Conversely, many helminths may cause allergic-type inflammation 42 
including symptoms of “classical” allergic disease. From an evolutionary perspective, 43 
individuals with an effective immune response against helminths may be more susceptible to 44 
allergy. This narrative review aims to inform readers on the most relevant up to date 45 
evidences on the relationship between parasites and allergy. Experiments in animal models 46 
have demonstrated the potential benefits of helminth infection or administration of helminth-47 
derived molecules on chronic inflammatory diseases, but clinical trials in humans have not so 48 
far demonstrated unequivocal clinical benefits. Nevertheless, there is sufficiently strong 49 
evidence to support the continued investigation of the potential benefits of helminth-derived 50 
therapies for the prevention or treatment of allergic and other inflammatory diseases.  51 
 52 
Keywords: Allergy, asthma, parasite infection, helminths, epidemiology, mechanisms. 53 
  54 
 55 
Abbreviations: 56 
AcK1 - a large family of ShK-related peptides 57 
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WHO – World Health Organization 91 
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 113 
Introduction 114 
The frequency of allergic disease has been rising in urban and urbanizing populations,
1
 while 115 
an overall decline in rates of infections has been observed. Studies of the inverse association 116 
between parasitic infections and allergy suggest the existence of a causal link.  117 
While humans can be infected with some 300 species of worms and over 70 species 118 
of protozoa
2
 we will focus on soil-transmitted helminths (STH). Worldwide, it is estimated 119 
1.5 billion humans are infected with one of these species.
3 
We will also refer to Schistosoma 120 
spp. that infect humans through contact of skin with water infested with larvae and it is 121 
estimated to infect 230 million people.
4
  122 
For example, Figure 1 shows typical features of a rural household in a village of 123 
Conde, Northeast Brazil, from 2005, in which the prevalence of helminth infections was 124 
83.5%.
5
 In the City of Salvador, 185 km away, the frequency of helminth infection among 125 
children was below 20%.
6
 An ecological study including all Brazilian municipalities reported 126 
hospitalization rates due to asthma were lower in those endemic for S. mansoni or for STH 127 
parasites.
7 
A typical urban underserved neighborhood of Salvador, is presented in Figure 2. 128 
Insert Figure 1. 129 
Typical features of a rural household in a village in the municipality of Conde, 130 
Northeast Brazil 131 
 132 
Insert Figure 2.  133 
Typical urban underserved neighborhood of Salvador, Northeast Brazil 134 
 135 
The purpose of this narrative review is to inform clinicians and researchers on the 136 
most current evidence on this topic, from epidemiological studies to mechanisms and 137 
molecules identified in helminths that are candidates for novel therapeutics. 138 
 139 
Global trends in parasite infections and allergy  140 
 141 
Global trends  142 
Allergic diseases are among the most common chronic diseases
1
 particularly in populations 143 
undergoing urbanization.
8
 Individual risk of allergy is considered to reflect a complex 144 
interaction between genetic predisposition and environmental exposures over the life course.
9
 145 
Geographic differences in the prevalence of allergy between and within populations is more 146 
likely to reflect exposures to common environmental factors that may either increase or 147 
decrease risk. The most consistent environmental exposures considered to reduce risk of 148 
allergy are those associated with rural residence and include farming, animal exposures
10
 and 149 
infections with parasites.
11
 150 
Protective immunity against STHs is mediated through type 2 immune mechanisms
11
 151 
and parasites can survive to cause chronic infections by modulating these allergic 152 
inflammatory responses. The prevalence of STH infections is declining worldwide. This 153 
reflects a combination of factors leading to reductions in transmission of these infections, 154 
including reductions in extreme poverty and improvements in the living environment (potable 155 
water and disposal of feces) and the wide availability of anthelmintic drugs. Reductions in 156 
STH prevalence, while beneficial, might raise concerns in case of being causally associated 157 
with allergy. 158 
 159 
Epidemiological evidence for associations between parasites and allergy  160 
There is evidence in support of protection against allergy by STH infections, but many 161 
studies in human populations present discordant effects.  162 
Meta-analyses of observational studies have shown differences in effects on asthma 163 
symptoms for different parasites: while A. lumbricoides was associated with an increased risk 164 
of asthma, hookworm infection was associated with a reduced risk.
12
 In contrast, studies that 165 
have measured the presence of Ascaris-specific IgE - recommended by some as a marker of 166 
infection in areas of low prevalence
13
 but perhaps more appropriately used as a marker of 167 
allergic sensitization to Ascaris - have shown consistently positive associations with asthma 168 
symptoms and even disease severity.
14,15
  169 
In the case of atopy, generally measured by allergen SPT reactivity, most cross-170 
sectional studies have shown inverse associations with STH infections.
16
 A meta-analysis of 171 
cross-sectional studies showed that current STH infections were protective against atopy, an 172 
effect that was consistent for all 3 of the most common STH infections and also 173 
schistosomiasis.
16
 STH infections are not alone in their SPT attenuating effects. A cross-174 
sectional study showed that, in addition to A. lumbricoides, several different childhood 175 
infections were independently and inversely associated with SPT, including visceral worm 176 
Toxoplasma gondii,  Herpes simplex and Epstein-Barr virus infections.
6
 This observation 177 
raises the possibility that rather than mediating protection directly, STH infections might be 178 
markers of poor environmental conditions that mediate protection through alternative 179 
mechanisms. Interestingly, in the study mentioned above, T. gondii was the only organism 180 
associated with a reduction in allergen-specific IgE in this population.
6
  181 
Few prospective studies have explored the effects of geohelminths on the 182 
development of allergy. It has been suggested that the key effects of protective environmental 183 
exposures, occur during early life during which there may be a limited window of 184 
opportunity for such exposures to mediate their effects.
9
 If this is the case, prospective studies 185 
of the effects of STH infections on allergy should start in early childhood, ideally before birth 186 
to measure any potential in utero effects of maternal STH infections. Four such prospective 187 
studies have been published to date; i) a birth cohort in Ethiopia where the prevalence of 188 
helminthiasis was considered to be too low to explore effects on wheeze and eczema to 5 189 
years;
17
 ii) an observational analysis within a randomized-controlled trial of anthelmintic 190 
treatment during pregnancy showed that maternal and childhood hookworm and childhood T. 191 
trichiura were associated with a reduced risk of eczema to 5 years;
18
 iii) a prospective study 192 
showed that T. trichiura infections during the first 5 years of life were associated with a 193 
reduced risk of SPT in later childhood;
19
 and iv) a birth cohort in a rural area did not show an 194 
effect of maternal STH infections on SPT, wheeze, or eczema during the first 3 years of 195 
life,
20
 but follow-up of the cohort is in progress to determine if childhood infections may 196 
affect risk of allergy at school age.
21
 197 
Another way used to test the causal link has been the interventional studies in which 198 
the protective exposure (i.e. STH) is removed through anthelmintic treatment thus intended to 199 
reverse any existing effects. If helminths are truly protective, one might expect to observe an 200 
increase in the prevalence of allergy in the group receiving treatment. Several intervention 201 
studies have inconsistent findings.
22,23,24
 None of the studies were able to show an effect on 202 
the prevalence of asthma symptoms, one showed that a single dose of anthelmintic drugs 203 
given during the latter part of pregnancy was associated with an increased risk of eczema in 204 
infancy,
22
 and two showed an increase in either the incidence
23
 or frequency
24
 of positive 205 
SPT after at least 1 year of treatments.  206 
Overall, the evidence suggests that A. lumbricoides infection and particularly Ascaris-207 
specific IgE is associated with an increased risk of asthma symptoms in endemic areas but 208 
that STH infections may reduce the prevalence of positive SPT, but not specific IgE (sIgE) to 209 
aeroallergens. There is still very limited evidence that STH infections protect against allergic 210 
symptoms in human populations, and the effects of early life exposures to STH infections on 211 
the development of allergy in childhood, either through maternal or childhood infections, is 212 
still insufficiently studied.  213 
In case of schistosomiasis, all published studies have been cross-sectional showing an 214 
inverse association between Schistosoma mansoni infection and SPT reactivity to common 215 
aeroallergens in most cases
16
. A recent study in Uganda was unable to demonstrate an 216 
association between S. mansoni infection and wheeze but an earlier study in Brazil showed 217 
that S. mansoni infection was associated with a milder form of asthma.
25
 218 
 219 
Host immune response against parasites  220 
Helminths are the largest organisms to infect vertebrate hosts, leading to the release of large 221 
quantities of parasite molecules that interact with the immune system. It might be expected 222 
that helminth infections should induce an overwhelming immune response, resulting in the 223 
elimination of the parasites, while causing potentially damaging inflammation. However, co-224 
evolution of hosts and parasites over millennia has allowed both host and parasite to survive 225 
through the development of mechanisms that dampen the host inflammatory response to the 226 
parasite or even allow the parasite to evade the host immune response, resulting in infections 227 
that are often asymptomatic.
11
 For example, Schistosoma spp adults, that live within the 228 
human vascular system, can survive for many years without inducing strong host 229 
inflammatory responses.
26
 230 
Although the most widely studied host immune response against helminths is the 231 
acquired Th2-type response, we shall discuss both innate and adaptive host immune 232 
responses to helminth parasites. The Th2 type response is characterized by the production of 233 
high levels of the cytokines IL4, IL5, IL9, IL10, IL13, IL21, IL33. These cytokines 234 
orchestrate immediate hypersensitivity that involves B cell class switching to IgG4 and IgE, 235 
eosinophilia, goblet cell hyperplasia and mastocytosis, alternative activation of macrophages, 236 
and the influx of inflammatory cells such as eosinophils that contribute to parasite killing. 237 
Such a response may control parasite numbers by killing them in tissues or expelling them 238 
from the intestinal lumen.
≈
 The host response to helminth infections is associated with 239 
allergic phenomena that are a consequence of killing or an attempt to kill or expel these 240 
parasites.
27
 Examples are shown in Table 1.  241 
Although helminth parasites are universal in inducing all or most of these Th2 242 
effector pathways in the host, the specific effector pathway mediating protection varies 243 
between different parasites, life cycle stages, and site of infestation. For example, the 244 
intestinal helminths, Heligmosomoides polygyrus and Trichinella spiralis, are expelled from 245 
the intestinal lumen by several Th2 effector pathways such as IgE-mediated activation of 246 
mucosal mast cells. Th1 responses may also have a role in protective immunity against some 247 
helminth parasites such as S. mansoni infection,
28 
 while the control of parasite burden in 248 
strongyloidiasis is highly dependent on type 2 responses.
29 
 249 
The parasite’s first contact with the host’s immune system is through CD11chigh DC 250 
which undergo alternative activation for example, in response to excretory-secretory (ES) 251 
molecules from the murine intestinal helminth parasites Heligmosomoides polygyrus and 252 
Nippostrongylus brasiliensis.
30
 Helminth molecules bind to TLR2, 3, 4 receptors on the 253 
dendritic cell membrane driving the acquired immune response from naive Th0 to a Th2 254 
profile.
31
  255 
An important group of innate immunity cells, the innate lymphocyte (ILCs), which 256 
lack B or T cells antigen specific receptors, and do not express myeloid or dendritic cell 257 
markers, has been shown to comprise three sub-sets: ILC1 (related to T1 profile), ILC2 258 
(related to T2) and ILC3 (related to ThI7).
32
 ILC2 produce a large set of T2 cytokines (IL4, 259 
IL5, IL9, IL13 and IL21) in response to stimulation with IL25, IL33 and TSLP
32
 and play an 260 
important role in protection against helminths. However, unlike Th2 cells, ILC2 are 261 
stimulated by alternatively activated macrophages (AAMΦs), express MHC-II, and are able 262 
to endocytose and process antigen.
33
 AAMΦs are phenotypically distinct from classically 263 
activated macrophages (CAMΦs) that are typical of Th1 type responses. AAMΦs do not 264 
produce IFNγ and instead of inducible nitric oxide synthase (iNOS), have upregulated 265 
expression of Arginase-1 that has higher affinity for arginine, competing with iNOS present 266 
in CAMΦs. AAMΦs are induced during infections with several helminth parasites.34 267 
Interestingly, an interaction between ILC2 and Th2 cells for maintaining AAMΦs in lungs of 268 
hookworm-infected mice has been reported.
35
  269 
Other immune cells reported to play a role in immunity against helminth infection are 270 
the Th17, derived from CD4(+) T cells after antigen maturation. Th17 cells are important for 271 
the clearance of several extracellular pathogens, such as bacteria and helminths.
36
 In S. 272 
japonicum-infected mice, there was an increase in Th17 cells following granuloma 273 
development, attributed to the presence of induced factors (e.g. TGFB, IL23 and IL21) in 274 
greater amounts than inhibitory factors (e.g. Treg and T2 cells, and IL-4).
37
  275 
Helminths have developed several mechanisms to suppress or avoid host anti-parasite 276 
responses. For example, S. mansoni has developed parasite stage-specific evasion strategies. 277 
Entry of cercariae through the skin is followed by the release of larval ES products (e.g. 278 
PGD2) that cause host cells to release PGE2.
38
 Both host and parasite-derived prostaglandins 279 
induce the production of IL10 in the skin that inhibits the migration of epidermal Langerhans 280 
cells to the invasion site.
39
  281 
The most remarkable evasion strategy used by helminths, particularly those dwelling 282 
within host tissues and in blood and lymphatic systems, is the down-modulation of the host 283 
immune system leading to a form of immunologic tolerance that, itself, may have effects on 284 
host responses to other infections and allergy. The cells mediating this effect are the Treg sub-285 
set of the CD4+ T lymphocytes that produce the immune modulatory cytokines IL10 and 286 
TGFB. The presence of regulatory cells is associated with a reduction in Th2 cells and the 287 
development of a modified type 2 immune response. Other cells involved are alternatively 288 
activated macrophages and B-regulatory cells.
11
  289 
 290 
Insert Figure 3. 291 
Schematic representation summarizing the findings from epidemiological studies of the 292 
relationships between helminth parasites and atopy and asthma 293 
 294 
Commonalities between the immune response to parasites and allergy 295 
The host immune response to helminth parasites has many features in common with allergy. 296 
Bronchial inflammation of atopic asthma is coordinated by cells of the adaptive immune 297 
system, but also by ILC2 of the innate response, which together induce a type 2 response.
40
 298 
During helminth infections type 2 immunity is initiated at the site of parasite invasion by 299 
epithelial cells, which release the alarmins IL25 and IL33 to prompt ILCs to produce IL13 300 
and other cytokines that are also involved in the pathoetiology of asthma. In the absence of 301 
either IL25 or IL33, resistance to helminth infections is severely impaired.
41
 Tregs cells have a 302 
dual role in helminth infections: they protect the host from excessive inflammatory responses 303 
during infection, but they also may decrease protective immunity and, thereby, permit 304 
parasite persistence.
42
 In the case of asthma, several studies have shown allergic patients to 305 
have lower numbers of Tregs in both the bronchoalveolar lavage and peripheral blood 306 
monocytes cells (PBMC).
43
 Thus, there are notable parallels between the immune responses 307 
associated with allergy and those observed in response to helminth infection.   308 
Host type 2 immune responses to parasites and allergens are induced by a limited 309 
number of protein families that contain allergens such as tropomyosins. There is extensive 310 
structural homology between allergens from helminths and other environmental sources.
44
 311 
Further, allergen homologues derived from parasites and aeroallergens do not just exhibit IgE 312 
cross-reactivity but can also induce cross-sensitization in murine models.
45
 Cross-reactivity 313 
between helminths and aerollergens has a number of important consequences including false-314 
positive reactions for specific IgE when used in the diagnosis of allergy and also a potential 315 
increase in morbidity caused by inflammatory reactions directed against cross-reactive 316 
allergens. In the case of the latter, cross-reactivity could help drive the exaggerated responses 317 
associated with inflammatory syndromes that have been reported in human helminth 318 
infections such as tropical pulmonary eosinophilia in the case of lymphatic filariasis
46
 and 319 
Loeffler’s syndrome in ascariasis.47 Likewise, it has been suggested that immune modulation 320 
during chronic helminth infections, which subvert Th2-mediated inflammation permitting 321 
parasite survival, could affect atopic responses to common aeroallergens through either 322 
bystander effects or immunological cross-reactivity.
45  
323 
 324 
Insert Figure 4. 325 
Helminths suppress autoimmunity and allergy via type 2 or regulatory immune response.
48
 326 
 327 
Genetic determinants of protection against helminths and risk of allergy  328 
 329 
Characterization of parasite genomes and subsequent comparison of parasites to more 330 
complex species such as mammalian hosts have contributed to our understanding of the 331 
mechanisms of parasite evolution and have provided evidence for the role of host–parasite 332 
interaction in genetic adaptation. An understanding of that genetic adaptation has elucidated 333 
candidate genes, which may drive susceptibility to other diseases of the immune system, 334 
including atopy and asthma.
49
 Thus, genetic variants affecting any of the classical key-roles 335 
inflammation inducing factors as well as proteins related to controlling inflammation through 336 
immune regulatory mechanisms such as Treg may play a role on both helminth resistance and 337 
allergic conditions. Genetic studies have highlighted common variants (MAF >10-30%) that 338 
affect allergy in many different ways. In Figure 5, an analysis using PANTHER version 11
50
 339 
is presented showing different pathways related to the main genes described in GWAS to 340 
date, in which one may observe 3 out of the top 4 pathways linked to asthma are related to 341 
interleukin signaling and inflammation. 342 
The genetic variants that affect protection against helminths and risk of allergy, can 343 
be organized in two main groups: those affecting Th2 immune response and those affecting 344 
regulatory mechanisms. 345 
 346 
Insert Figure 5: 347 
Pathway analysis using Panther 11 version for the top SNPs associated in GWAS for 348 
asthma to date. 349 
 350 
 351 
Variants that affect Th2 immune response 352 
 353 
Common genetic variants of type 2 immune signaling relating to allergy and asthma provide 354 
credence to the hypothesis that the origin of these allergy-promoting variants derives from 355 
evolutionary mechanisms and their selection occurred in the presence of widespread, 356 
endemic helminth infection.
51
 A region on chromosome 5, 5q31-q33, for example, has been 357 
associated with resistance to S. mansoni through the presence of genes such as those of 358 
granulocyte-macrophage factor (CSF2), IL3, IL4, IL5 and IL13, that are important in 359 
protective immunity against S. mansoni.
52
 The same locus (5q31-q33) has been linked to 360 
asthma and atopy. Other relevant loci that are also linked to asthma are 7q and 21q.
53
   361 
In terms of asthma susceptibility, several immune molecules have been associated 362 
with asthma/allergy. In both GWAS and candidate genes studies some 200 genes have been 363 
associated with asthma or related phenotypes. Among these genes, there are those related to a 364 
possible modulation of plasma tIgE levels.
54
 Association studies of genes encoding the 365 
epithelial cell-derived cytokines, IL33 and TSLP, and the IL1RL1 gene encoding the IL33 366 
receptor, ST2, highlight the central roles for innate immune response pathways that promote 367 
the activation and differentiation of Th2 cells. These genes are the most consistent variants 368 
associated with asthma, allergy and helminth infections across ethnically diverse 369 
populations.
55
  370 
In this context, GWAS studies for allergic diseases have pinpointed IL33 and IL1RL1 371 
as key susceptibility genes for allergic asthma, underscoring the pivotal role of this pathway 372 
in the pathophysiology of this diseases.
56
 Studies involving the genes codifying the IL33/ST2 373 
route have been widely replicated in different populations,
57
 confirming their association with 374 
asthma
58
 and blood eosinophilia.
59
 The mechanism whereby the IL33/ST2 axis induces Th2-375 
inflammation was demonstrated recently.
60
 Local airway soluble ST2 (sST2) levels, as well 376 
as circulating plasma sST2 levels, contribute to neutralization of IL33 in the tissues.  377 
The role of human genetic determinants of IL33/ST2 in helminth infection is poorly 378 
understood. Using a generalized estimating equation model, three SNPs associated with 379 
higher SWAP specific IgE/IgG4 (a measure of resistance to S. mansoni) were found.
61
 The 380 
most significant SNP mapped to intron 1, and the allele, which has been shown to confer 381 
asthma risk in an African-American population, also conferred protection against 382 
schistosomiasis.  383 
Major polymorphisms within the 5q31-q33 genomic region, previously associated 384 
with resistance to S. mansoni infection have been studied.
52,53
 The region includes several 385 
genes related to immune function including IL-4, IL-5, and IL-13 genes in the Th2 cluster.  386 
Resistance to S. haematobium was associated with the IL13-1055T/T genotype
62
 which has 387 
also been implicated in asthma exacerbations.
63
 Further, a functional IL13 polymorphism, 388 
rs1800925T, was shown to contribute to the risk of late-stage schistosomiasis caused by S. 389 
japonicum.
64
 In another study, two quantitative traits, tIgE levels (representing Th2 pathway 390 
activation) and S. mansoni egg counts, that reflect host immunity to helminths were 391 
investigated, providing a unique opportunity for the genetic dissection of the Th2 pathway in 392 
the context of schistosomiasis.
7
 Significant associations were seen between two functional 393 
variants on the IL13 gene and S. mansoni egg counts, indicating IL13 to be protective, but no 394 
associations of IL13 gene variants with tIgE levels. Since the functional effect of both 395 
variants on the gene product, IL13, is to increase its amount or activity, this finding suggests 396 
IL13 functions to increase anti-helminth immunity, and functional variants may be an 397 
evolutionary vestige of selective forces that may now favor atopic phenotypes.
5
  398 
 399 
Variants that affect immune regulatory mechanisms 400 
Alterations in regulatory cytokine levels are believed to play an important role in mediating 401 
immune suppression in helminth immune response. Genetic variants affecting IL10 and 402 
TGFB1 may be associated with both asthma/allergy and heminthiasis. We described a variant 403 
(rs3024496, G allele) in the IL-10 gene associated with the suppression of IL-10 production 404 
in A. lumbricoides antigen-stimulated cultures of peripheral blood leukocytes, and also, other 405 
variants within the same gene, were both positively associated with atopy and asthma and 406 
negatively associated with helminth co-infections.
65
  407 
Several IL10 promoter polymorphisms have been extensively studied. Some variants 408 
were significantly associated with high PBMC proliferative responses to Onchocerca 409 
volvulus antigen.
66
 One of these promoter variants, the G-1082A was also associated with 410 
immune-related diseases including type 2 diabetes, multiple sclerosis, and asthma.
67
 411 
Moreover, the same variant was associated with pediatric asthma.
68
 In an endemic area for S. 412 
mansoni alleles at the three promoter SNPs were associated with high tIgE levels in the same 413 
direction as in atopic individuals, but not with egg counts. IL10 promoter polymorphisms 414 
appear to influence non-specific tIgE levels, but not schistosomiasis-specific immunity.
7
 415 
Genetic polymorphisms in TGFB1 are associated with airway responsiveness and 416 
exacerbations in children with asthma.
69
 Common variants in TGFB1 gene affect both 417 
asthma/allergy and helminth infections. We demonstrated a negative association between 418 
rs1800470 (C allele), atopic wheezing and markers of allergy. In contrast, a positive 419 
association was observed between the haplotype ACCA and T. trichiura and A. lumbricoides 420 
infection. This later haplotype was also associated with increased IL10 production.
70
 421 
The main cellular source of both IL10 and TGFB1 are Tregs, critical for the 422 
maintenance of immune homeostasis. The activation of FOXP3 transcriptional factor is 423 
pivotal for Tregs function. The human FOXP3 gene is located on the X-chromosome 424 
(Xp11.23) and because of sex differences among X-variants, insufficient efforts have been 425 
made to include X variants in GWAS. Ppolymorphisms in the FOXP3 gene have been 426 
evaluated in association studies for allergy
71 
but only a few studies on asthma have been 427 
reported. A study reported a significant interaction between SNPs in FOXP3-IL2R genes and 428 
sIgE for worm eggs and asthma.
72
 The SNPs rs2294019 and rs5906761 were associated with 429 
the risk of egg sensitization only in females.
71
 The heterozygote genotype for rs3761547 was 430 
a risk factor for allergic rhinitis, and this association was reproduced in gene-gene interaction 431 
analysis with rs3761548.
72
  432 
The immune regulation of allergic disease results not only from protective 433 
environmental factors including helminths, but also from genetic factors relating to IL10 434 
production or hyperactivation of type 2 immune responses. From an evolutionary perspective, 435 
the selective advantage acquired by humans able to mount an efficient protective immune 436 
response to helminth infections may make them more vulnerable to atopy and asthma. 437 
 438 
Immunoregulation by helminths and clinical practice   439 
Insert Table 1. 440 
Examples of helminth infections and the allergic-type inflammatory responses with which 441 
they are associated. 442 
Treatment of allergic diseases with systemic corticosteroids at immunosuppressive 443 
doses increase the risk of opportunistic infections. The helminth reported to affect immune 444 
suppressed hosts most frequently is Strongyloides stercoralis, occasionally resulting in 445 
uncontrolled dissemination of the parasite in the potentially fatal hyper-infection syndrome. 446 
Strongyloides hyperinfection has been associated also with other immunosuppressive drugs, 447 
lymphomas, and infection with HTLV-1 virus.
73
 Because of the presumed central role of IgE 448 
in protective immunity against helminth parasites, treatment of severe asthma with anti-IgE 449 
antibody raised concerns about risk of severe or disseminated helminth infections. A 450 
multicentre randomized controlled trial of omalizumab for the treatment of asthma and 451 
rhinitis was safe in a population at risk of STH infections, although there was a modest 452 
increase in geohelminth infection.
74
 The same safety concerns will be present in populations 453 
at risk of helminthiasis for other immunomodulatory compounds for treatment of allergic 454 
diseases, particularly those targeting specific type 2 effector pathways such as anti-IL5 and 455 
anti-IL13/IL4.  456 
Helminth infections induce cellular immune hyporesponsiveness.
11
 Such 457 
hyporesponsiveness has been associated with suboptimal vaccine responses.
75,76
 Among 458 
pregnant women, soluble parasite antigens cross the placenta and modify fetal immune 459 
responses in such a way as to possibly affect vaccine responses in childhood.
77
 Modification 460 
of the host immune response to helminths affects how humans respond immunologically to 461 
other pathogens such as those causing malaria
78
 and tuberculosis,
79
 however, effects on 462 
clinically measurable outcomes are less clear.  463 
 464 
Insert Clinical Notes I. 465 
Notes of relevance for clinical allergy practice on immunopathology of helminth infections. 466 
 467 
Reports have indicated possible benefits of helminth infections on autoimmune 468 
diseases, inflammatory bowel disease, and even in the metabolic syndrome.
80
 For example, 469 
an inverse association between lymphatic filariasis and type II Diabetes was reported,
81
 and 470 
past infection with S. japonicum was associated with a lower prevalence of metabolic 471 
syndrome.
82
 Intestinal helminth infections were inversely associated with risk factors for 472 
cardiovascular diseases, such as body mass index and lipid levels.
83
   473 
Insert Clinical Notes II. 474 
Notes of relevance on protection against allergy and other chronic diseases. 475 
 476 
Exploring the immunomodulatory potential of helminths and helminth molecules  477 
Helminth infection and immunomodulation of diseases 478 
An observational study of patients with multiple sclerosis, who had acquired gastrointestinal 479 
helminth infections, reported remission of multiple sclerosis for over 4 years. Patients 480 
infected with parasites had reduced inflammatory cytokine responses and enhanced 481 
production of IL10 as well as TGFB. Six of these subjects were followed up and remission 482 
continued into the sixth year, when four patients were offered anthelmintic treatment due to 483 
gastrointestinal problems. Subsequently their multiple sclerosis activity resumed while IL10 484 
and TGFB levels declined.
84 
 485 
Experimental infections of humans with live parasites employing either the pig 486 
whipworm, T suis, or the human hookworm, N. americanus have been reported.
85
 The 487 
premise is that the immune system can be modulated with amelioration or remission of the 488 
inflammatory disease. In the case of treatment with T. suis, parasite eggs are administered 489 
orally. Initial studies reported a beneficial effect on Crohn’s disease and ulcerative colitis.86 490 
T. suis eggs have been used to treat other immune disorders. A randomized controlled trial 491 
tested the efficacy of T. suis for the treatment allergic rhinitis in Denmark but showed no 492 
efficacy.  Although T. suis infection generated a measurable anti-parasite response, infection 493 
did not affect allergen-specific responses.
87
 Patients with Crohn’s patients were infected with 494 
N. americanus, with the majority showing improvements in symptom scores.
88
 A trial of N. 495 
americanus in patients with coeliac disease was unable to demonstrate clinical benefit.
89 
A 496 
small randomized control trial in patients with asthma showed no significant benefit of 497 
hookworm infection on clinical symptoms, bronchial responsiveness or SPT reactivity.
90
 498 
 What may be the reasons for the disappointing findings of clinical trials to date? 499 
Experimental animal models have demonstrated helminth parasites reduce allergic reactivity, 500 
but most studies have been designed to prevent the development of allergic reactivity rather 501 
than treat established disease. Only a handful of studies have reported the effects of these 502 
infections on already established allergic reactivity.
91
 Most of the experimental data available 503 
suggest that once the allergic reaction is established, helminth infections can do little to revert 504 
the disease process, raising the question whether there is any reasonable possibility of 505 
obtaining benefit through infections of individuals with active disease. Nonetheless, there are 506 
sufficient doubts with respect to optimal timing of treatment, the dose and systemic versus 507 
non-systemic infections, to justify future well-designed and justified randomized-controlled 508 
trials of helminth therapy for inflammatory conditions.  509 
  510 
Tests with helminth molecules as immunomodulatory candidates 511 
Recombinant proteins can reproduce the biological effects observed in infections with live 512 
worms. In experimental models of inflammatory disease, recombinant proteins derived from 513 
helminth molecules induce anti-inflammatory and inhibit pro-inflammatory cytokine 514 
production, promote regulatory cell recruitment and immune deviation.
92
 515 
In mouse models, helminth ES molecules, and helminth-derived synthetic molecules 516 
have shown usefulness in treating or preventing the development of inflammatory diseases 517 
such as inflammatory bowel diseases, type 1 Diabetes, multiple sclerosis, rheumatoid arthritis 518 
and asthma. The synthetic production of ES-derived immune modulators avoids concerns 519 
raised by the use of live organisms.
93
 Further, the molecule-based helminth treatment offers 520 
the advantage of delivery directly to the site of pathology.  521 
 We present in Table 2 a summary of pre-clinical and clinical studies of helminth 522 
molecules for the treatment of chronic inflammatory conditions affecting humans.   523 
Insert Table 2. 524 
Helminth molecule candidates for the treatment of inflammatory diseases. 525 
 526 
Discussion  527 
There is conflicting evidence of an inverse association between exposure to helminth 528 
infections and human chronic inflammatory diseases including allergic conditions. A possible 529 
causal relationship is supported largely by the findings from experimental animal models, 530 
while evidence from human studies has been equivocal. Evidence from clinical trials of live 531 
helminth parasites has been disappointing.  532 
 One explanation for the associations between allergy and helminths in 533 
epidemiological studies is the genetic evolutionary advantage of mounting strong type 2 534 
responses protective against helminth infection although increasing the risk of allergy.
65
 535 
Alternatively, the sort of environmental and unhygienic living conditions where parasite 536 
infections are likely to occur also expose populations to multiple other microorganisms which 537 
may contribute to the modulation of inflammatory responses.
94,95
 Moreover, there is evidence 538 
that several other contextual factors not always controlled for in observational studies might 539 
contribute to the inverse association between helminthes and allergy. Such factors include 540 
diet, nutrition, obesity, gut microbiome, physical activity, exposure to air pollution, stress and 541 
use of vaccines and antibiotics, all of which are related to an urbanized lifestyle, which has 542 
clearly been an important risk factor for allergy.
96,97
 543 
 How do we interpret the negative results of clinical trials of live helminth infections 544 
when helminth infections or helminth-derived molecules have proved so effective in 545 
controlling animal models of inflammatory diseases? The effects of helminth infections in 546 
humans are related to parasite burden and duration of infection. Clearly, there are safety and 547 
ethical concerns with treating humans with large infectious doses and maintaining infections 548 
for period of years that may be required to induce clinically relevant immune modulatory 549 
effects. Further, trials in humans have attempted to modify preexisting disease while most 550 
animal models have studied the ability of helminths to prevent disease.  551 
  552 
Conclusions  553 
There is consolidated evidence from studies in humans for a negative association of helminth 554 
infection with allergy, although the effect seems to vary by helminth species, parasite burden, 555 
and age of infection. Helminth infections may also provoke symptoms of allergy, although 556 
such allergic inflammation tends to be modulated during chronic infections. Experiments in 557 
animal models of chronic inflammatory diseases have demonstrated the potential benefits of 558 
helminth infection or the use of helminth-derived molecules against allergic disease, but 559 
clinical trials in humans have been disappointing. We still have an inadequate understanding 560 
of the complex interplay between helminths and allergy and there is a need for more studies 561 
in humans and experimental studies in animal models to understand these interactions more 562 
fully. Certainly, the exploitation of helminth-derived molecules for the treatment of 563 
inflammatory conditions offers promising new avenues for research and development. 564 
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 914 
 915 
 916 
 917 
Clinical Notes Box I.  918 
Notes of relevance for clinical allergy practice on immunopathology of helminth infections. 919 
 920 
 Accuracy of allergy testing 921 
when dealing with patients from endemic areas for helminth infections, an allergy workup 922 
including specific IgE may be more sensitive than SPT, but in subjects with a very high 923 
total IgE, in vitro tests may be false positive 924 
 Interpretation of total IgE and blood eosinophilia 925 
elevated total IgE and peripheral blood eosinophilia may indicate helminth infection  926 
 Potential reduction in efficacy of vaccines for prevention of infectious diseases  927 
it is important children and adults are free of worms for optimal efficacy of vaccines 928 
 Risks of prolonged use of systemic corticosteroids and immunobiological supressors of 929 
T2 inflammation mediators (Anti-IgE, Anti-IL5, Anti-IL4/13)  930 
treatment of severe asthma with continuous oral corticosteroids, Anti-IgE, Anti-IL5 or 931 
Anti-IL4/13 poses risk of helminth superinfection. It is advisable to observe the patient 932 
closely, investigate and treat if necessary, when living or coming from a region that is 933 
endemic for worms.  934 
 935 
 936 
Clinical Notes Box II.  937 
Note of relevance on protection against allergy and other chronic diseases 938 
 939 
 Inverse association between helminth infection and allergy and other chronic 940 
diseases there is compelling evidence of a strong inverse association between 941 
infection by various helminths and biomarkers of chronic inflammatory diseases and 942 
allergy 943 
 A causal association is plausible  944 
a direct causality is plausible, taking into consideration experimental studies in animal 945 
models and humans 946 
 No robust association between helminth infection and protection against diseases 947 
we found no robust evidence for causal associations between helminth infection and 948 
clinically relevant protection against disease, however 949 
 Exposure to helminths occur in a diverse environment that may be itself protective  950 
in the real world, exposure to helminths often occur in a markedly different 951 
environmental, ethnical and lifestyle context, including contrasts in ancestrality, 952 
physical activity, diet, nutrition, stress, exposure to air pollution and to 953 
microorganisms 954 
 A protective environment may overshadow the effects of helminth infection 955 
the potential influence of multiple factors in the health and diseases balance may 956 
overshadow the impact of exposure to parasites 957 
 The inverse associations may not be directly causal  958 
the inverse associations between helminth infections and biomarkers of chronic 959 
inflammatory diseases and allergy may not be directly causal, but linked to conditions 960 
related to parasite infections 961 
 962 
FIGURE LEGEND 963 
 964 
Figure 1. Typical features of a rural household in a village in the municipality of 965 
Conde, Brazil, in which the prevalence of helminth infections was 83.5% (Grant et al, 966 
2008) (picture taken in 2005).  967 
 968 
Figure 2. Typical urban underserved neighborhood of Salvador, Brazil, in which the 969 
prevalence of helminth infection among children was below 20% (Alcantara-Neves et 970 
al, 2011).  971 
 972 
Figure 3. Schematic representation summarizing the findings from epidemiological 973 
studies on the relationships between helminth parasites, atopy and asthma. 974 
 975 
Figure 4. Helminths suppress autoimmunity and allergy via type 2 or regulatory 976 
immune response. Immunomodulatory molecules (IMs) of parasites activate innate 977 
immune cells that promote either Th2 or Treg responses. IMs that induce TGFβ, IL10 978 
by dendritic cells (DCs) or macrophages (Mθ) prime IL10 or TGFβ-producing Treg 979 
cells suppress Th2 responses,Th1 or Th17 responses. A separate set of helminth-980 
derived IMs activate type 2 innate cells, including basophils, M2 macrophages, and 981 
type 2 innate lymphoid cells (ILC2) and induce innate IL-4 production, which drives 982 
differentiation of Th2 cells. Th2 cells and type 2 innate immune cells can suppress 983 
Th1 and Th17 responses (modified from Finlay et al, 201448). 984 
 985 
Figure 5. Pathway analysis using Panther 1187 version for the top SNPs associated 986 
in GWAS for asthma to date. 987 
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Hookworm 
Strongyloides stercoralis 
Enterobius vermicularis 
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Tropical dysentery syndrome 
Ground itch/allergic enteritis 
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Schistosomiasis 
S. mansoni 
S. haematobium 
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Cercarial dermatitis/acute schistosomiasis/urticaria/ ‘asthma-
like’ syndrome 
 
Filariasis 
Wuchereria bancrofti 
Onchocerca volvulus 
Loa loa 
 
Tropical pulmonary eosinophilia/acute lymphangitis 
Sowda/acute popular onchodernatitis/punctate keratitis 
Calabar swellings 
Others 
Toxocara spp. 
Anisakis spp. 
Paragonimus spp. 
Trchinella spiralis 
Echinococcus granulosus 
Ancylostoma braziliense 
 
Visceral larva migrans/’asthma-like’ syndrome 
‘gastroallergic’/asthma-like syndrome/urticara/anaphylaxis 
Asthma-like syndrome 
Acute trichinosis 
Acute anaphylaxis associated with rupture of cyst 
Cutaneous larva migrans 
 
 
Table 1. Examples of helminth infections and the allergic-type inflammatory responses with which they are associated. 
Tables
Table 2. Helminth molecule candidates for the treatment of inflammatory diseases.  
 
Molecule Study phase Treatment Results References 
Excretory/secretory-62 animal models rheumatoid 
arthritis and 
systemic lupus 
erytematosus 
reduce disease severity 
and progression 
Rodgers at al, 
2015159 
Neutrophil inhibitory Factor 
(NiF) 
animal models and 
humans (Phase I/II) 
acute stroke, 
allergen induced 
lung 
inflammation and 
diabetic 
retinopathy 
no benefit in human stroke, 
favourable results in 
mouse models of lung 
inflammation and 
retinopathy 
Krams et al, 
2003;160 
Schnyder-
Candrian et al, 
2012;161 
Veenstra et al, 
2013162 
Migration inhibitory Factor 
(MiF) 
animal models colitis and 
allergic airway 
inflammation 
favorable Cho et all, 
2011;163 Park et 
al, 2009164 
Cystatins animal models colitis and 
allergic airway 
inflammation 
favorable Whelan et al, 
2014165 
Helminth defense 
molecules 
animal models LPS-induced 
inflammation 
favorable Alvarado et al, 
2017166 
Anti-inflammatory protein-2 
(AIP-2) 
animal models model of asthma favorable Navarro et al, 
2016167 
TGFB Pathway 
Manipulation 
studies in vitro molecular biology 
stage 
promising  Freitas et al, 
2009168 
Prostaglandin E2 (PGE2) studies in vitro molecular biology 
stage 
promising  Liu et al, 2013169 
ShkT domains   animal models and 
humans (Phase I and 
II) 
human psoriasis unknown results Beeton et al, 
2006170 and 
NCT02435342 
AcK1 and BmK1 studies in vitro immunology 
stage 
promising  Steinfelder et al, 
2016171 
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